Clinical trial
VELCADE,Rituximab,Cyclophosphamide and Decadron
NCT00413959 · Oncology Specialists, S.C., Other · Terminated
Key facts
| NCT number | NCT00413959 |
|---|---|
| Title | VELCADE,Rituximab,Cyclophosphamide and Decadron |
| Official title | Phase II Study Investigating the Efficacy of VELCADE®, Rituximab, Cyclophosphamide and Decadron (VRCD Regimen) in Front-line Therapy of Patients With Low-grade Non-Hodgkin's Lymphoma |
| Acronym | VRCD |
| Lead sponsor | Oncology Specialists, S.C., Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin, B-Cell |
| Intervention type | Drug |
| Interventions | VELCADE®, Rituximab, Cyclophosphamide, Decadron |
| Enrollment | 12 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Dec 20, 2006 |
| Last update posted | Sep 19, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: